Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock. (HSHC00582434)
Primary Purpose
Septic Shock
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Hydrocortisone hemisuccinate
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock
Eligibility Criteria
Inclusion Criteria:
- patients over 18 years old
- septic shock in accordance with the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee criteria. Septic shock was managed in accordance with the 2004 edition of the Surviving Sepsis Campaign guidelines.
- no minimal vasopressor dose was needed to enter the trial.
Exclusion Criteria:
- medical history of adrenal insufficiency
- ongoing corticosteroid treatment
- pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
200 mg group
300 mg group
Arm Description
Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Outcomes
Primary Outcome Measures
Mortality
The primary end point was to determine a difference in 28-day mortality between the 200-mg and 300-mg groups.
Secondary Outcome Measures
Incidence of permanent shock between groups
Permanent shock (PS) was defined as permanent catecholamine support (epinephrine or norepinephrine) in the ICU, from the onset of septic shock to death without a period of reversal.
Incidence of shock relapse between groups
Shock relapse (SR) was defined as recurrence of septic shock requiring catecholamine resumption.
Incidence of post hydrocortisone hemodynamic rebound between groups
Post hydrocortisone hemodynamic rebound (PHHR) was defined as SR within 48 hours after hydrocortisone cessation.
Incidence of adverse events between groups.
Incidences of hemorrhagic events, superinfections and the amount of needed insulin were compared between the two groups.
Full Information
NCT ID
NCT02768740
First Posted
May 10, 2016
Last Updated
May 20, 2016
Sponsor
Association Niçoise de Réanimation Médicale
1. Study Identification
Unique Protocol Identification Number
NCT02768740
Brief Title
Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.
Acronym
HSHC00582434
Official Title
Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Association Niçoise de Réanimation Médicale
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
We performed a multicenter, prospective, randomized, double-blind, pilot study in four adult medical intensive care units. Patients presenting septic shock were rapidly administered one of two regimens of hydrocortisone, either a 50-mg intravenous bolus every six hours during seven days (200-mg group) or a 100-mg initial bolus followed by a continuous infusion of 300 mg daily for five days (300-mg group). Hydrocortisone was stopped abruptly at the end of treatment.
Detailed Description
Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent. The placebo was saline serum supplied as 10 ml ampoules. The study drugs were administered according to two protocols. In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days. In the two groups, hydrocortisone was stopped abruptly at the end of treatment. The investigators had the choice or resuming hydrocortisone at the end of the fifth day if deemed necessary.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
200 mg group
Arm Type
Active Comparator
Arm Description
Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
Arm Title
300 mg group
Arm Type
Experimental
Arm Description
Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Intervention Type
Drug
Intervention Name(s)
Hydrocortisone hemisuccinate
Other Intervention Name(s)
Saline solution as placebo
Intervention Description
In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Primary Outcome Measure Information:
Title
Mortality
Description
The primary end point was to determine a difference in 28-day mortality between the 200-mg and 300-mg groups.
Time Frame
28-day
Secondary Outcome Measure Information:
Title
Incidence of permanent shock between groups
Description
Permanent shock (PS) was defined as permanent catecholamine support (epinephrine or norepinephrine) in the ICU, from the onset of septic shock to death without a period of reversal.
Time Frame
28-day
Title
Incidence of shock relapse between groups
Description
Shock relapse (SR) was defined as recurrence of septic shock requiring catecholamine resumption.
Time Frame
28-day
Title
Incidence of post hydrocortisone hemodynamic rebound between groups
Description
Post hydrocortisone hemodynamic rebound (PHHR) was defined as SR within 48 hours after hydrocortisone cessation.
Time Frame
28-day
Title
Incidence of adverse events between groups.
Description
Incidences of hemorrhagic events, superinfections and the amount of needed insulin were compared between the two groups.
Time Frame
28-day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients over 18 years old
septic shock in accordance with the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee criteria. Septic shock was managed in accordance with the 2004 edition of the Surviving Sepsis Campaign guidelines.
no minimal vasopressor dose was needed to enter the trial.
Exclusion Criteria:
medical history of adrenal insufficiency
ongoing corticosteroid treatment
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles Bernardin, M.D.
Organizational Affiliation
Association Niçoise de Réanimation Médicale
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
The data are available for additional analysis
Learn more about this trial
Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.
We'll reach out to this number within 24 hrs